Community-acquired pneumonia: an unfinished battle
Med Clin North Am. 2011 Nov;95(6):1143-61.
doi: 10.1016/j.mcna.2011.08.007.
Epub 2011 Oct 5.
Authors
Girish B Nair 1, Michael S Niederman
Affiliation
●1Pulmonary and Critical Care Medicine, Winthrop-University Hospital, Mineola, NY, USA.
●
PMID:
22032432
●
PMCID:
PMC7127066
●
DOI:
10.1016/j.mcna.2011.08.007
Abstract
Community-acquired pneumonia remains a common illness with substantial morbidity and mortality. Current management challenges focus on identifying the likely etiologic pathogens based on an assessment of host risk factors, while attempting to make a specific etiologic diagnosis, which is often not possible. Therapy is necessarily empiric and focuses on pneumococcus and atypical pathogens for all patients, with consideration of other pathogens based on specific patient risk factors. It is important to understand the expected response to effective therapy, and to identify and manage clinical failure at the earliest possible time point. Prevention is focused on smoking cessation and vaccination against pneumococcus and influenza.
Copyright © 2011 Elsevier Inc. All rights reserved.
Publication types
●
Review
MeSH terms
●
Algorithms
●
Biomarkers / blood
●
Community-Acquired Infections / diagnosis
●
Community-Acquired Infections / drug therapy
●
Community-Acquired Infections / epidemiology
●
Community-Acquired Infections / prevention & control
●
Community-Acquired Infections / therapy
●
Comorbidity
●
Critical Care
●
Humans
●
Legionnaires' Disease / diagnosis
●
Lung / diagnostic imaging
●
Lung Diseases / microbiology
●
Medical History Taking
●
Physical Examination
●
Pneumonia / diagnosis
●
Pneumonia / drug therapy
●
Pneumonia / epidemiology
●
Pneumonia / prevention & control
●
Pneumonia / therapy*
●
Practice Guidelines as Topic
●
Prognosis
●
Radiography
●
Risk Factors
●
Severity of Illness Index
●
Sputum / cytology
Substances
●
Biomarkers